AMP | Karius

Oral Platform Presentation

Saturday, November 9

2:30 – 2:45 p.m.
Rooms 318-323, Level 300


Microbial Cell-free DNA Sequencing for Multiplexed Detection and Quantitation of Cytomegalovirus, Epstein-Barr Virus, and BK Virus

Presented by Tim Blauwkamp, PhD | Chief Scientific Officer, Karius

Dr. Blauwkamp, a co-founder of Karius, is a biomedical scientist with 15 years experience managing and conducting research in molecular biology, regenerative medicine, and next-generation sequencing. He was previously Head of Molecular Biology at Moleculo, where he ran scientific research and lab operations until the company’s acquisition by Illumina. He continued to lead a technology development group within Illumina, creating new genomics tools and authoring several patent applications.


Wednesday, November 6

2:00 – 2:50 p.m.
Room 318-320


Implementation of the Karius® Test, a Quantitative Next-Generation Sequencing (NGS) Test, which Identifies Microbial Cell-Free DNA from Plasma in Patients with Severe Infections

Presented by Carol Quinter, PhD | Clinical Laboratory Advisor, Karius

Dr. Quinter currently serves as a Clinical Laboratory Advisor at Karius as well as the Director of Laboratory Clinical Services at Alimetrix Corporation. Her prior experience includes three decades at Kettering Health Network in Dayton, Ohio, where she served in several leadership roles, including microbiology, molecular technology, clinical quality and infection, prevention and control. Under her leadership, the laboratory quality program was integrated into the hospital quality program, setting standards for laboratory test algorithms which were evidence based, promoted best practice, and resulted in improved patient and financial outcomes. Dr. Quinter received her Bachelor of Science degree and Master of Science degree from The Ohio State University. She completed her Ph.D. at the College of Medicine of Ohio State University in a unique program which included tenure in the Infectious Diseases Division and the clinical laboratory.

Workshop Description

The Karius Test uses microbial cell-free DNA from bacteria, DNA viruses, fungi, and parasites to identify pathogens throughout the body. This workshop describes the considerations of implementing the analytically and clinically validated Karius Test into clinical practice. A review of clinical cases is included.



Saturday, November 9

9:45 - 10:45 a.m.
Poster Presentations
Poster Hall

Poster #TT007

Advanced Quality Control System for Clinical Metagenomic Sequencing Assays

CLIA-certified and CAP-accredited laboratories implementing next-generation sequencing (NGS) lab-developed tests are continuously investing in quality control (QC) systems. Most QC systems monitor a handful of measurements that are recommended by guidelines, including positive and negative controls, sequencing depth, and read quality. However, metagenomic sequencing for infectious disease diagnostics must be robust to a broader range of biases, including those arising from environmental contaminants, and require additional QC measurements compared to a standard NGS assay.

Our lab tracks thousands of metrics per assay, and it is infeasible for one to monitor all of these or determine if an observed anomaly is statistically significant. We present an automated QC framework that monitors thousands of metrics, such as the presence of microbial DNA in reagents, across space and time and identifies aberrations that are statistically significant.



Schedule a Meeting with the Karius Team